Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.05 (8.333%)
Open: 0.625
High: 0.625
Low: 0.625
Prev. Close: 0.625
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Centamin Falls After Gold Production Drops

Mon, 09th Jul 2018 10:08

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------Just Eat, up 2.4%. RBC Capital raised the online takeaway platform to its Top Pick list.BHP Billiton, up 1.8%. Shares in the Anglo-Australian miner were higher after Reuters reported on Friday that oil major BP is in the lead to acquire the US onshore shale oil and gas assets from BHP after submitting an offer over USD10 billion. BP was down 1.0%.----------FTSE 100 - LOSERS----------Hargreaves Lansdown, down 0.9%. JPMorgan downgraded the funds supermarket to Underweight from Neutral. ----------FTSE 250 - WINNERS----------Stobart Group, up 4.8%. The support services firm said on Saturday that its former chief executive had been re-elected and then immediately dismissed. A majority of shareholders, 51%, voted Andrew Tinkler back onto the board at the company's annual general meeting on Friday, the results of which were delayed until Saturday evening. Tinkler's re-election and his subsequent dismissal were announced within Stobart's Saturday AGM results. In its Saturday statement, Stobart noted that Tinkler's election was passed by the required majority but justified its decision to remove him from the board once again. Tinkler stepped down as chief executive last year but remained on the board. He was removed altogether after accusations of "subverting the company for his own interests" and attempting to cash GBP30 million worth of shares, the Daily Mail said.TalkTalk Telecom Group, up 3.5%. JPMorgan raised the home phone and broadband provider to Neutral from Underweight. ----------FTSE 250 - LOSERS----------Centamin, down 7.5%. The gold miner said second quarter gold production from its Sukari mine in Egypt dropped 25% as underground grades fell below forecast. For the three months to June 30, the miner produced 92,803 ounces of gold compared to 124,641 in the comparative year ago period. In the six months to June 30, production fell 7% to 217,099 ounces form 233,828 ounces year-on-year. In May, the company revised its annual production guidance of between 505,000 and 515,000 ounces at a cash cost of production of USD625 to USD640 per ounce produced and an all-in sustaining cost of USD875 to USD890 per ounce sold. "We have experienced several challenges this year, resulting in the revision of our full year guidance in May," said Chief Executive Officer Andrew Pardey.----------OTHER MAIN MARKET AND AIM - WINNERS----------Legendary Investments, up 17%. The investment company recorded double digit growth in investments and net assets in its recently-ended financial year. In the year to the end of March, the company invested GBP6.2 million versus GBP4.3 million the year before. Net assets saw a 28% increase to GBP6.0 million from GBP4.7 million. During the year, one of Legendary's holdings, Virtualstock Holdings received an investment of GBP4.5 million from European venture capital firm Notion Capital. Legendary holds GBP66 million worth of stake in Virtualstock. In addition, Legendary converted its shares in its Kyrgyz gold asset to shares in Circle Oil Tunisia in December 2017, following Circle Oil Tunisia's acquisition by Dunraven Resources, meaning the the company now holds a 2.0% stake in Dunraven.----------OTHER MAIN MARKET AND AIM - LOSERS----------N4 Pharma, down 52%. The drug reformulation company said that its sildenafil reformulation clinical trial has not met its key target endpoints. The company said that the product formulation will need to be reviewed to assess what changed need to be made to make the reformulated drug viable to N4 Pharma's patent position. "This part of the process of drug reformulation is always going to be a challenge and whilst this preliminary data is clearly disappointing, we will need to see the full set of results expected around the end of August to understand the detailed implications for the formulation," said Chief Executive Officer Nigel Theobald.----------
More News
14 Sep 2020 10:52

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

Read more
14 Sep 2020 09:04

N4 Pharma plunges as Covid-19 progress stalls

(Sharecast News) - N4 Pharma lost more than a third of its value after the company said its potential Covid-19 vaccine delivery method did not produce a positive result at stage 3 of tests.

Read more
1 Sep 2020 21:35

IN BRIEF: N4 Pharma Signs Technology Transfer & Manufacturing Contract

IN BRIEF: N4 Pharma Signs Technology Transfer & Manufacturing Contract

Read more
1 Sep 2020 09:19

N4 Pharma chooses Ardena as contract manufacturing partner

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has appointed the API and nanomedicines business unit of Ardena as its contract development and manufacturing organisation partner for the technology transfer and upscaling manufacture of 'Nuvec', it announced on Tuesday.

Read more
12 Aug 2020 14:18

N4 Pharma Shares Spike 30% On Successful Covid-19 Study

N4 Pharma Shares Spike 30% On Successful Covid-19 Study

Read more
6 Jul 2020 14:13

IN BRIEF: N4 Pharma's Nuvec Shows Promise In Oral Vaccine Delivery

IN BRIEF: N4 Pharma's Nuvec Shows Promise In Oral Vaccine Delivery

Read more
28 May 2020 14:49

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

Read more
28 May 2020 09:47

N4 Pharma completes first stage proof of concept work for Nuvec

(Sharecast News) - Pharmaceutical group N4 Pharma has completed the first phase of Covid-19 proof of concept work for Nuvec, the group's novel delivery system for cancer treatments and vaccines.

Read more
18 May 2020 15:39

N4 Pharma To File Nuvec Patent Across Europe, US, Other Major Markets

N4 Pharma To File Nuvec Patent Across Europe, US, Other Major Markets

Read more
13 May 2020 14:55

N4 Pharma Raises GBP2 Million To Fund Covid-19 Research Project

N4 Pharma Raises GBP2 Million To Fund Covid-19 Research Project

Read more
13 May 2020 11:30

N4 Pharma raises ?2.03m via oversubscribed placing

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has raised ?2.03m through an oversubscribed placing of 50,731,250 new ordinary shares, it announced on Wednesday, at a price of 4p each.

Read more
24 Apr 2020 14:33

N4 Pharma Files Patent For Nuvec Opportunities In Viral Vector Market

N4 Pharma Files Patent For Nuvec Opportunities In Viral Vector Market

Read more
24 Apr 2020 09:30

N4 Pharma files for new UK patent on 'Nuvec'

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has filed a new UK patent application around both the ability of its 'Nuvec' delivery system ability to be used to manufacture viral vectors, and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments.

Read more
16 Apr 2020 15:59

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
16 Apr 2020 14:57

UK TRADING UPDATE SUMMARY: NHS Uses Induction Healthcare's Mobile App

UK TRADING UPDATE SUMMARY: NHS Uses Induction Healthcare's Mobile App

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.